To counter the growing public health problem posed by antimicrobial resistance and the diminishing arsenal of effective therapies to combat those pathogens, governments are implementing regulatory policies and funding programs designed to create an environment that will encourage biopharmas to commit research and development resources toward the development of novel antibiotics and antifungals. Read More
The old saying "many hands make quick work" doesn't apply to drug manufacturing for use in clinical trials, according to a new study from The Tufts Center for the Study of Drug Development (CSDD) looking at single-source vs. multivendor manufacturing at contract development and manufacturing organizations (CDMOs). Read More
